Swedish Orphan Biovitrum AB 2012 Annual Report with Sustainability Disclosures
Company: Swedish Orphan Biovitrum AB
Sector: Manufacturing
Country: Sweden
Year: 2012
Type: Annual Report with Sustainability Disclosures
Pages: 114
The report describes 2012 group revenue of SEK 1,923.2 M and positive top-line results from phase III studies of long-acting treatments for haemophilia A and B. It also highlights continued phase III development of Kiobrina for preterm infants, alongside growth in key product areas. The company reports total energy consumption of 17,845 MWh at its Stockholm and Umeå facilities.
Services
From bulk PDFs to structured indicators and machine-readable documents.